Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 157 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Upper Respiratory Tract Infection Clear all
Recruiting Phase 4 Interventional

Gastrointestinal Dysmotility on Aspiration Risk

NCT05455359
View directory record Official record
Conditions
Esophageal Motility Disorders, Gastric Motor Dysfunction, Aspiration Pneumonia, Gastro Esophageal Reflux
Interventions
Prucalopride, Famotidine
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 4, 2026, 1:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

NCT04032093
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSV vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
145
States / cities
Birmingham, Alabama • Cullman, Alabama • Glendale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 4, 2026, 1:56 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

NCT03656510
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
JNJ-53718678, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
28 Days to 3 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Madera, California • Ventura, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 4, 2026, 1:56 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

NCT04886596
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Placebo, RSVPreF3 OA vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
26,675 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 4, 2026, 1:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.

NCT02878330
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MEDI8897, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
Up to 365 Days
Enrollment
1,453 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
60
States / cities
Birmingham, Alabama • Anaheim, California • Downey, California + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 4, 2026, 1:56 PM EDT
Completed No phase listed Observational

Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age

NCT01754428
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 24 Months
Enrollment
2,432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Oct 4, 2026, 1:56 PM EDT
Not listed Not applicable Interventional

Dialogue Around Respiratory Illness Treatment

NCT02943551
View directory record Official record
Conditions
Respiratory Disease, Acute Respiratory Infection, Respiratory Infection, Upper Respiratory Infection
Interventions
Online Tutorial, Webinars, Booster Sessions, Feedback Reports, Parent Survey
Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Months to 10 Years
Enrollment
2,728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
20
States / cities
Paragould, Arkansas • Eureka, California • Durango, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 4, 2026, 1:56 PM EDT
Completed Phase 1 Interventional

Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers

NCT02484417
View directory record Official record
Conditions
Upper Respiratory Tract Infection
Interventions
RSV A2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 4, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

NCT03275389
View directory record Official record
Conditions
Influenza, Human
Interventions
D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03, D-SUIV cH8/1N1+AS01, D-SUIV cH5/1N1+AS01, D-SUIV cH11/1N1+AS01, D-SUIV cH8/1N1, D-SUIV cH5/1N1, D-SUIV cH11/1N1, Placebo, Fluarix Quadrivalent
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 39 Years
Enrollment
470 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
5
States / cities
South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 4, 2026, 1:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19

NCT04548895
View directory record Official record
Conditions
Covid19, Community-Acquired Respiratory Tract Infection
Interventions
Observational measurement of biometric data. No change to health care provided.
Device
Lead sponsor
Health Stream Analytics, LLC
Industry
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pasco, Washington
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 4, 2026, 1:56 PM EDT
Terminated Phase 2 Interventional Results available

Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract

NCT04633187
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
16 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 4, 2026, 1:56 PM EDT
Recruiting Not applicable Interventional

The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)

NCT05762302
View directory record Official record
Conditions
Lower Respiratory Tract Infection
Interventions
MeMed BV test
Diagnostic Test
Lead sponsor
MeMed Diagnostics Ltd.
Industry
Eligibility
18 Years to 99 Years
Enrollment
1,316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Jacksonville, Florida • Kansas City, Kansas • Brooklyn, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 4, 2026, 1:56 PM EDT
Recruiting Not applicable Interventional

Artificial Intelligence Diagnostic Decision Support to Reduce Antimicrobial Prescriptions in Young Children With Colds

NCT06876259
View directory record Official record
Conditions
Acute Otitis Media (AOM), Upper Respiratory Infection
Interventions
Standard Clinical Ear Exam, AI app ear exam and diagnosis
Diagnostic Test
Lead sponsor
Timothy Shope
Other
Eligibility
6 Months to 24 Months
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 4, 2026, 1:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nasal Swab Study to Explore the Nasal Microbia

NCT02535442
View directory record Official record
Conditions
Common Cold
Interventions
Not listed
Lead sponsor
Kimberly-Clark Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 4, 2026, 1:56 PM EDT
Completed Phase 4 Interventional Results available

Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds

NCT00189475
View directory record Official record
Conditions
Upper Respiratory Infection
Interventions
Montelukast, Placebo
Drug
Lead sponsor
Deborah Gentile
Other
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 4, 2026, 1:56 PM EDT
Terminated Phase 4 Interventional

A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

NCT04505098
View directory record Official record
Conditions
Covid19, Atherosclerosis, Cardiovascular Diseases, Upper Respiratory Tract Infections
Interventions
Icosapent ethyl
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years and older
Enrollment
39,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 4, 2026, 1:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Stopping Upper Respiratory Infections and Flu in the Family: The Stuffy Trial

NCT00448981
View directory record Official record
Conditions
Respiratory Tract Infections, Common Cold
Interventions
Education, Hand Sanitizer, Face Masks
Behavioral · Device
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
Not listed
Enrollment
2,788 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 4, 2026, 1:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Transfer Factor to Prevent Upper Respiratory Tract Infections in Healthy Adults

NCT01106183
View directory record Official record
Conditions
Upper Respiratory Tract Infections Due to Influenza or Rhinovirus
Interventions
transfer factor, Placebo
Dietary Supplement
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 40 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 4, 2026, 1:56 PM EDT
Completed No phase listed Observational

Diagnosing Respiratory Disease in Children Using Cough Sounds 2

NCT03392363
View directory record Official record
Conditions
Pneumonia, Bronchiolitis, Asthma Exacerbation, Croup, Reactive Airway Disease, Upper Respiratory Disease, Viral Lower Respiratory Tract Infections, Lower Respiratory Disease
Interventions
Recordings of Infants and Children's Cough Sounds
Device
Lead sponsor
ResApp Health Limited
Industry
Eligibility
29 Days to 12 Years
Enrollment
1,470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Boston, Massachusetts • Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 4, 2026, 1:56 PM EDT
Terminated Phase 3 Interventional Results available

Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria

NCT03219164
View directory record Official record
Conditions
Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Months to 18 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
San Francisco, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 4, 2026, 1:56 PM EDT
Completed Not applicable Interventional Results available

Use of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory Infection (URI)

NCT04468204
View directory record Official record
Conditions
Upper Respiratory Infection
Interventions
SinuSonic Device, Sham SinuSonic Device
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 4, 2026, 1:56 PM EDT
Completed No phase listed Observational

Prospective Clinical Evaluation of the FilmArray® Lower Respiratory Tract Infection (LRTI) Panel

NCT03361670
View directory record Official record
Conditions
Lower Resp Tract Infection
Interventions
Observational Study
Other
Lead sponsor
BioFire Diagnostics, LLC
Industry
Eligibility
Not listed
Enrollment
1,689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Los Angeles, California • Maywood, Illinois • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 4, 2026, 1:56 PM EDT
Completed Not applicable Interventional Results available

Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections

NCT01062256
View directory record Official record
Conditions
Infection
Interventions
Placebo, Guaifenesin, Buckwheat Honey
Drug · Other
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Indianapolis, Indiana • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 4, 2026, 1:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Vitamin A and Zinc: Prevention of Pneumonia (VAZPOP) Study

NCT00228254
View directory record Official record
Conditions
Pneumonia, Diarrhea, Acute Upper Respiratory Tract Infections
Interventions
Zinc (12.5 mg/day), vitamin A 10,000 IU per week
Drug
Lead sponsor
Tufts University
Other
Eligibility
6 Months to 36 Months
Enrollment
2,582 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2005 · Synced Oct 4, 2026, 1:56 PM EDT